Skip to content

Primary Irritation Patch Test on Humans with Normal and Sensitive Skin

Evaluation of Dermatological Safety of Investigational Products by 24 hour Patch Test under Complete Occlusion on Healthy Human Subjects - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/032138
Enrollment
48
Registered
2021-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: 1. Rheumatil Spray, 2. Maha mash tail 3. Tuvrak tail 4. Shankhapushpi tail 5, Maha Vishagarbh tail 6. Panchaguna Tail : Study will be a single application test. 40 µl of the test pro

Sponsors

Dabur India Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects in age group 18 - 65 years (both the ages inclusive) 2.Healthy male & female subjects with skin types normal, dry and oily 3.Subjects with Fitzpatrick skin type III to V. 4.Subjects in good health condition as per the medical screening criteria with no disease state or physical condition that the investigator believes could interfere with the interpretation of the data. 5.Subject able to read, understand and sign an appropriate informed consent form indicating her willingness to participate. 6.Subjects willing to give a voluntary written informed consent. 7.Subjects willing to maintain the patch test in position for 24 hours. 8.Subject having not participated in a similar investigation in the past two weeks. 9.Subjects willing to come for regular follow up visits. 10.Subjects ready to follow instructions during the study period.

Exclusion criteria

Exclusion criteria: 1. Subjects with infection, allergy on the tested area. 2. Subjects with skin allergy, antecedents or atopic subjects. 3. Subjects with known hypersensitivity to any of the study products or constituents. 4.Subjects with any significant skin pathology in the investigational area, 5. Athletes and subjects with history of excessive sweating. 6. Subjects with cutaneous disease which may influence the study result. 7. Subjects using any topical or systemic treatment that could interfere with the study treatments/assessments within the last 4 weeks prior to participation in the study and during the study. 8. Subjects on oral corticosteroid. 9.Subjects participating in any other cosmetic or therapeutic trial. 10. Subjects who are currently pregnant or lactating or planning to become pregnant in the period of study. 11. Subjects with any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness. 12. More than one subject selected/participating from one family/household.

Design outcomes

Primary

MeasureTime frame
Evaluation of Dermatological Safety of Investigational Products By 24 Hours Patch Test Under Complete Occlusion on Adult Healthy Human Subjects with Normal skin type and sensitive Skin TypeTimepoint: 0 hr, 24 hr, 48 hr & 7 days

Secondary

MeasureTime frame
NilTimepoint: NIL

Countries

India

Contacts

Public ContactRitambhara

Dabur India Limited

sasibhushan.vedula@dabur.com01203378405

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026